Key Slides on Hepatitis B Pretreatment Evaluation

Clinical Care Options (CCO) expert Dr. Yasuhito Tanaka on HCC risk prediction in patients with chronic hepatitis B using the novel serum biomarker HBcrAg

Yasuhito Tanaka, MD, PhD Released: May 6, 2021

Brief presentation by Dr. Anna Christina dela Cruz on the various methods to assess liver inflammation and fibrosis and translating results into practice from Clinical Care Options (CCO)

Anna Christina L. dela Cruz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 20, 2021 Expired: April 19, 2022

Download free slides reviewing key data and AASLD guidance on methods to evaluate liver fibrosis and inflammation in patients with HBV infection

Anna Christina L. dela Cruz, MD Released: April 20, 2021

W. Grace L. H. Wong 博士，来自 Clinical Care Options (CCO)的慢性 HBV 患者的 HCC 风险评估和跨学科管理

Grace LH Wong, 医学博士 Released: April 16, 2021